Compare AAON & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAON | BMRN |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.3B |
| IPO Year | 1995 | 1999 |
| Metric | AAON | BMRN |
|---|---|---|
| Price | $82.33 | $58.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 27 |
| Target Price | ★ $134.75 | $91.62 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | 0.77 |
| Revenue | ★ $1,442,076,000.00 | $1,313,646,000.00 |
| Revenue This Year | $59.43 | $21.30 |
| Revenue Next Year | $17.53 | $14.36 |
| P/E Ratio | ★ $74.00 | $77.75 |
| Revenue Growth | ★ 20.11 | 17.62 |
| 52 Week Low | $73.19 | $49.26 |
| 52 Week High | $150.46 | $70.98 |
| Indicator | AAON | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 33.31 |
| Support Level | $75.02 | $58.03 |
| Resistance Level | $88.17 | $60.36 |
| Average True Range (ATR) | 3.49 | 1.35 |
| MACD | 1.19 | -0.57 |
| Stochastic Oscillator | 46.99 | 12.53 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which derives maximum revenue, engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.